Calidi Biotherapeutics stock was up 171.84% in pre-market trading on Wednesday, following a 39.47% rally yesterday. However, ...

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

Calidi Biotherapeutics Inc. CLDI stock surged by 39.47% in the after-hours trading session on Tuesday. The stock price ...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease.

Calidi Biotherapeutics Inc. is taking a bold approach to this challenge with a next-generation platform designed to deliver genetic medicines directly to both primary and metastatic tumors.

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today ...

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. ('Calidi” or the 'Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of ...

Calidi Biotherapeutics Inc. (NYSE American: CLDI) ('Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to ...

Calidi Biotherapeutics secures $4.6 million through warrant exerciseCalidi Biotherapeutics is developing targeted therapies designed to deliver genetic medicines to disease sites. The company’s ...

Ladenburg Thalmann & Co, Inc. is acting as the exclusive placement agent for the offering.